Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9723.124 | 1.0261 | 1.0532 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9723.124 | 0.9564 | 0.9113 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9723.124 | 1.1128 | 1.2299 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9723.124 | 0.8266 | 0.6477 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9723.124 | 0.8338 | 0.6622 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9723.124 | 0.8776 | 0.7512 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9723.124 | 0.8609 | 0.7173 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9723.124 | 0.8408 | 0.6765 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9723.124 | 0.7471 | 0.4864 | 0.9827 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9760.026 | 1.0377 | 1.0702 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9760.026 | 0.9659 | 0.9364 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9760.026 | 1.0275 | 1.0512 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9760.026 | 0.7991 | 0.6225 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9760.026 | 0.7464 | 0.5227 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9760.026 | 0.7734 | 0.5738 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9760.026 | 0.7387 | 0.5079 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9760.026 | 0.7418 | 0.5139 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9760.026 | 0.7356 | 0.5020 | 1.0724 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 10127.123 | 0.7368 | 0.4116 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 10127.123 | 0.9820 | 0.9590 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 10127.123 | 0.6613 | 0.2479 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 10127.123 | 0.8860 | 0.7421 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 10127.123 | 0.7612 | 0.4650 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10127.123 | 0.7754 | 0.4962 | 0.8767 | |
| SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10127.123 | 0.7664 | 0.4764 | 0.8767 |